bioAffinity
  • Home
  • Publications
  • News
  • About
  • Contact
  • Investor Relations
Select Page

Meet BioAffinity Technologies: Fly exclusive interview with CEO Maria Zannes

by Dale Harrison | Dec 28, 2022 | Articles, News

Meet BioAffinity Technologies: Fly exclusive interview with CEO Maria Zannes DECEMBER 28, 2022 As published in the The Fly By: Jessica de Sa-Mota BioAffinity focuses on the development of noninvasive, early-stage cancer diagnosis and targeted cancer treatment In an...

SA Cancer Diagnostic Company Adding Research Talent

by Dale Harrison | Dec 23, 2022 | Articles, News

SA Cancer Diagnostic Company Adding Research Talent DECEMBER 23, 2022 As published in the San Antonio Business Journal By: W. Scott Bailey – Senior Reporter, San Antonio Business Journal BioAffinity Technologies Inc. is making multiple personnel moves in an effort to...

Maria Zannes named to TEXAS 100 Influential professionals to watch in 2023

by Dale Harrison | Dec 21, 2022 | Articles, News

TEXAS 100 Influential professionals to watch in 2023 DECEMBER 21, 2022 As published in the San Antonio Business Journal By: Colin Pope – Editor, Austin Business Journal Our annual Texas 100 is a list of impactful Texans who will likely play crucial roles in the...

After going public, SA company charts next course

by Dale Harrison | Nov 29, 2022 | Articles, News

After going public, SA company charts next course NOVEMBER 29, 2022 As published in the San Antonio Business Journal By: W. Scott Bailey – Senior Reporter, San Antonio Business Journal Fresh off of filing its first earnings report as a publicly traded company, San...

San Antonio cancer biotech follows IPO with patent win in China

by Dale Harrison | Nov 2, 2022 | Articles, News

San Antonio cancer biotech follows IPO with patent win in China NOVEMBER 2, 2022 As published in the San Antonio Business Journal By: By W. Scott Bailey – Senior Reporter, San Antonio Business Journal The People’s Republic of China has awarded a Certificate of Patent...

Behind the Deal: Company’s decision to go public drawing capital and attention to SA

by Dale Harrison | Sep 30, 2022 | Articles, News

Behind the Deal: Company’s decision to go public drawing capital and attention to SA SEPTEMBER 30, 2022 As published in the San Antonio Business Journal By: W. Scott Bailey – Senior Reporter, San Antonio Business Journal The move by bioAffinity Technologies Inc. to...
« Older Entries

Categories

  • Articles (15)
  • Events (34)
  • News (40)
  • Press Releases (56)
  • Publications (15)

Recent Posts

  • bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research January 24, 2023
  • Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning January 23, 2023
  • bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments January 4, 2023
  • Meet BioAffinity Technologies: Fly exclusive interview with CEO Maria Zannes December 28, 2022
  • bioAffinity President & CEO to meet with institutional investors and bankers during J.P. Morgan Annual Healthcare Conference in San Francisco, January 9-12, 2023 December 28, 2022

Learn About CyPath Lung

CyPath Lung Test

Main Menu

  • Home
  • Publications
  • News
  • About
  • Contact
  • Investor Relations
Copyright © 2023 bioAffinity Technologies, Inc.